Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Additional information:

The conduct of skin sensitisation studies according to established protocols is not feasible, as dermally applied solutions of cyanide salts would result in high acute systemic toxicity before immunologic sensitisation occurs. Risk management measures, including gloves and other barriers, as dictated by classification according to Annex VI of Regulation (EC) 1272/2008, will protect against sensitisation as well as acute toxicity effects and irritation.


Migrated from Short description of key information:
The systemic toxicity of cyanides is sufficiently high that acute toxicity and possibly lethality occur before inflammatory and immune responses would result in sensitisation .

Respiratory sensitisation

Endpoint conclusion
Additional information:

Hydrogen cyanide (as the vapour form of KCN) has high acute toxicity, with an LD50 of 68 mg/m3 for 6 hours in the rat, is the endpoint of concern for the inhalation route of exposure. For human exposure, the LD01 has been estimated to be 43 mg/m3 for a 4 hour exposure.


Migrated from Short description of key information:
No data exists on respiratory sensitisation

Justification for classification or non-classification

There is insufficient evidence to classify cyanide salts as dermal or respiratory sensitisers. The listing of cyanide salts in Annex VI of Regulation (EC) No. 1272/2008 does not indicate that cyanide salts are sensitisers. The systemic toxicity of cyanides is sufficiently high that systemic intoxication and death are likely to occur before the development of immune effects in the skin or lung. The risk management measures designed to protect against acute systemic toxicity will also protect against sensitisation.